Publications
| Comparative in vitro activity of four respiratory fluoroquinolones (Resp-FQ) against clinical isoltes of strains of Streptococcus pneumoniae (SP). |
Authors: D.C. Richardson, R.J. Davidson, L.A. Mandell, K. Weiss, D. Bast, J. deAzavedo, D.E. Low.
Background: Resp-FQs are being recommended and widely used for the treatment of community-acquired pneumonia because of increasing multidrug resistance in SP. There is limited data comparing all of these agents "head to head".
Method: We performed broth microdilution testing using NCCLS recommendations and interpretative criteria on 2421 clinical isolates of SP obtained from ongoing cross-Canada surveillance between 1997 and 2000.
Results: Resistance rates were 6.1%, 2.1%, 1.8%, 1.0%, and 0.3% for ciprofloxacin (cip), levofloxacin (lev), gatifloxacin (gat), moxifloxacin (mox), and gemifloxacin (gem), respectively. We used a breakpoint of 31µg/ml to define gem resistance. The MICs of the 147 cip-resistant strains (MIC34µg/ml) are summarized below:
Conclusions: Greatest activity against both cip-sensitive (MIC£2µg/ml) and cip-resistant strains is as follows: gem>mox>gat>lev.
Presented At:
41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 12/16/2001.
|
|
|
|
|
©Copyright
1999 Microbiology Department, Mount Sinai Hospital, Toronto, ON, Canada.
All rights reserved. Last Modified
|
|
